Regulatory T cells inhibit CD8+ T-cell tissue invasion in human skin graft-versus-host reactions

Transplantation

Volumn 94, Issue 5, 2012, Pages 456-464

  Mavin, Emily ^a   Ahmed, Shaheda S ^a   O'Boyle, Graeme ^a   Turner, Brie ^b   Douglass, Stephen ^a   Norden, Jean ^a   Collin, Matthew ^a   Ali, Simi ^a   Dickinson, Anne ^a   Wang, Xiao Nong ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b Research and Development   (Australia)

Author keywords

CD8 T cell migration; Graft versus host disease; Hematopoietic stem cell transplantation; Regulatory T cells

Indexed keywords

CHEMOKINE RECEPTOR CXCR; CHEMOKINE RECEPTOR CXCR10; CHEMOKINE RECEPTOR CXCR11; CHEMOKINE RECEPTOR CXCR3; CUTANEOUS LYMPHOCYTE ASSOCIATED ANTIGEN; GAMMA INTERFERON; UNCLASSIFIED DRUG;

ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CD8+ T LYMPHOCYTE; CELL ACTIVITY; CELL ADHESION; CELL FUNCTION; CELL INFILTRATION; CELL INVASION; CELL MIGRATION; CELL THERAPY; CONTROLLED STUDY; ENZYME INHIBITION; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; REGULATORY T LYMPHOCYTE; SKIN DISEASE;

ANTIGENS, LY; CELL ADHESION; CELLS, CULTURED; CHEMOKINE CXCL10; CHEMOKINE CXCL11; CHEMOKINE CXCL9; CHEMOTAXIS, LEUKOCYTE; COCULTURE TECHNIQUES; FLOW CYTOMETRY; GRAFT VS HOST DISEASE; GRAFT VS HOST REACTION; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON-GAMMA; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CXCR3; SKIN; T-LYMPHOCYTES, REGULATORY; TISSUE CULTURE TECHNIQUES;

EID: 84866325034     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31826205d6     Document Type: Article

References (39)

1. Ferrara JL, Levine JE, Reddy P, et al. Graft-versus-host disease. Lancet 2009; 373: 1550.
2. Kunkel EJ, Butcher EC. Chemokines and the tissue-specific migration of lymphocytes. Immunity 2002; 16: 1.
3. Sackstein R. A revision of Billingham's tenets: the central role of lymphocyte migration in acute graft-versus-host disease. Biol Blood Marrow Transplant 2006; 12(1 suppl 1): 2.
4. Wysocki CA, Panoskaltsis-Mortari A, Blazar BR, et al. Leukocyte migration and graft-versus-host disease. Blood 2005; 105: 4191.
5. Waldman E, Lu SX, Hubbard VM, et al. Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine. Blood 2006; 107: 1703.
6. Duffner U, Lu B, Hildebrandt GC, et al. Role of CXCR3-induced donor T-cell migration in acute GVHD. Exp Hematol 2003; 31: 897.
7. Piper KP, Horlock C, Curnow SJ, et al. CXCL10-CXCR3 interactions play an important role in the pathogenesis of acute graft-versus-host disease in the skin following allogeneic stem-cell transplantation. Blood 2007; 110: 3827.
8. + T-and NK-cell fractions. Bone Marrow Transplant 2009; 43: 863.
9. Kanda N, Shimizu T, Tada Y, et al. IL-18 enhances IFN-FYinduced production of CXCL9, CXCL10, and CXCL11 in human keratinocytes. Eur J Immunol 2007; 37: 338.
10. Teraki Y, Miyake A, Takebayashi R, et al. In vivo evidence for close association of CLA expression and E-selectin binding by T cells in the inflamed skin. J Dermatol Sci 2004; 36: 63.
11. Catalina MD, Estess P, Siegelman MH. Selective requirements for leukocyte adhesion molecules in models of acute and chronic cutaneous inflammation: participation of E-and P-but not L-selectin. Blood 1999; 93: 580.
12. Muessig A, Reiger C, Gentilini C, et al. Increase in CLA expression by circulating T-cells in chronic cutaneous GvHD: a novel marker for less-invasive disease monitoring? Bone Marrow Transplant 2005; 35: S337.
13. He S, Cao Q, Qiu Y, et al. A new approach tothe blocking of alloreactive T cellYmediated graft-versus-host disease by in vivo administration of anti-CXCR3 neutralizing antibody. J Immunol 2008; 181: 7581.
14. Proudfoot AE, Power CA, Schwarz MK. Anti-chemokine small molecule drugs: a promising future? Expert Opin Investig Drugs 2010; 19: 345.
15. Schall TJ, Proudfoot AE. Overcoming hurdles in developing successful drugs targeting chemokine receptors. Nat Rev Immunol 2011; 11: 355.
16. + regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005; 6: 345.
17. + regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003;9: 1144.
18. Di Ianni M, Falzetti F, Carotti A, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011; 117: 3921.
19. Brunstein CG, Miller JS, Cao Q, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 2011; 117: 1061.
20. + immunoregulatory T cells prevent graft-versus-host-disease by inhibiting activation/differentiation of pathogenic T cells. J Immunol 2006; 176: 1266.
21. + T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood 2004; 104: 3804.
22. + regulatory T cells protects from lethal acute GVHD. Blood 2005; 105: 2220.
23. + T-cellYmediated graft-versus-host reaction requires their presence during priming. Transplantation 2009; 88: 188.
24. Wang XN, Collin M, Sviland L, et al. Skin explant model of human graft-versus-host disease: prediction of clinical outcome and correlation with biological risk factors. Biol Blood Marrow Transplant 2006; 12: 152.
25. Dickinson AM, Wang XN, Sviland L, et al. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor his-tocompatibility antigens. Nat Med 2002; 8: 410.
26. Wang XN, Lange C, Schulz U, et al. Interleukin-10 modulation of allor-eactivity and graft-versus-host reactions. Transplantation 2002; 74: 772.
27. + dendritic cells to skin tissues ex vivo causes infiltration and activation of HA-1Yspecific cytotoxic T cells. Biol Blood Marrow Transplant 2011; 17: 69.
28. Bacchetta R, Gregori S, Serafini G, et al. Molecular and functional characterization of allogantigen-specific anergic T cells suitable for cell therapy. Haematologica 2011; 95: 2134.
29. + regulatory T cells during acute graft-versus-host disease. Blood 2005; 106: 3300.
30. Hasegawa H, Inoue A, Kohno M, et al. Therapeutic effect of CXCR3-expressing regulatory T cells on liver, lung and intestinal damages in a murine acute GVHD model. Gene Ther 2008; 15: 171.
31. Ukena SN, Velaga S, Geffers R, et al. Human regulatory T cells in al-logeneic stem cell transplantation. Blood 2011; 118: e82.
32. Mohan K, Cordeiro E, Vaci M, et al. CXCR3 is required for migration to dermal inflammation by normal and in vivo activatedT cells: differential requirementsbyCD4 and CD8 memory subsets. Eur J Immunol 2005; 35: 1702.
33. Flier J, Boorsma DM, Bruynzeel DP, et al. The CXCR3 activating chemokines IP-10, Mig, and IP-9 are expressed in allergic but not in irritant patch test reactions. J Invest Dermatol 1999; 113: 574.
34. Flier J, Boorsma DM, van Beek PJ, et al. Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation. J Pathol 2001; 194: 398.
35. + cells controlling a pathogenic CD4 response inhibit cytokine differentiation, CXCR-3 expression, and tissue invasion. J Immunol 2004; 173: 2942.
36. Dimitroff CJ, Kupper TS, Sackstein R. Prevention of leukocyte migration to inflamed skin with a novel fluorosugar modifier of cutaneous lymphocyte-associated antigen. J Clin Invest 2003; 112: 1008.
37. Faaij CM, Lankester AC, Spierings E, et al. A possible role for CCL27/CTACK-CCR10 interaction in recruiting CD4 T cells to skin in human graft-versus-host disease. Br J Haematol 2006; 133: 538.
38. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402.
39. Lerner KG, Kao GF, Storb R, et al. Histopathology of graft-vs.-host reaction (GvHR) in human recipients of marrow from HL-AYmatched sibling donors. Transplant Proc 1974; 6: 367.